AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. 11:35:17 2024-04-12 EDT 5-day change 1st Jan Change
11,064 GBX +0.93% Intraday chart for AstraZeneca PLC +4.18% +4.38%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Global markets live: BP, Apple, Vodafone, Ford, Lockheed Martin... Our Logo
Weight-Loss Drugs Like Wegovy Don't Cause Suicidal Thoughts, EU Says DJ
European Medicines Agency Finds No Increased Suicide Risk Linked to Weight-loss Drugs MT
EU regulator finds no link between weight-loss drugs and suicidal thoughts RE
Fitch Affirms AstraZeneca Rating on Stable Position in Pharmaceutical Sector MT
Keymed Biosciences Advances Solid Tumors Drug With First Patient Study MT
AstraZeneca Executives' Compensation Policy Passes With Low Shareholder Approval DJ
AstraZeneca shareholders approve 2024 pay policy in boost to CEO Soriot RE
AstraZeneca shareholders approve 2024 pay policy at AGM RE
European Equities Close Lower on Thursday as ECB Leaves Interest Rates Unchanged MT
FTSE 100 edges lower as financials drag RE
FTSE 100 Closes Down 0.5% Dragged by Financial Stocks After ECB Holds Rates DJ
Dwindling US Fed cut hope unnerves markets AN
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading MT
AstraZeneca Says US FDA Approves Fasenra to Treat Children Aged 6 to 11 With Severe Asthma MT
AstraZeneca: new approval for Fasenra in the USA CF
Wholesale Prices Rise Less Than Expected in March as US Equity Futures Waver Pre-Bell MT
AstraZeneca?s FASENRA Approves for Treatment of Children Aged 6 to 11 with Severe Asthma by the US Food and Drug Administration CI
Europe takes hit on nerves ahead of ECB decision AN
AstraZeneca's Board Increases 2024 Dividend by 7% to $3.10 per Share MT
Astra plans 7% dividend hike for 2024 after no rise in 2023 AN
European markets mixed ahead of ECB decision AN
AstraZeneca: 7% increase in annual dividend CF
Astra promises dividend hike; Darktrace ups guidance AN
AstraZeneca Plans 7% Increase to FY24 Dividend MT
Chart AstraZeneca PLC
More charts
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
137.7 USD
Average target price
162 USD
Spread / Average Target
+17.60%
Consensus
  1. Stock Market
  2. Equities
  3. AZN Stock
  4. News AstraZeneca PLC
  5. Berenberg: AstraZeneca Set for More Lung Cancer Success After Recent Pipeline Gains